Merck is set to face a significant revenue challenge beginning in 2028 as it loses patent protections for Keytruda, which currently accounts for roughly half of the company's income. Despite management's optimism about a potential $70 billion annual revenue from its pipeline in a decade, the immediate impact of Keytruda's patent loss raises questions about Merck's financial stability and strategic direction.
“Merck · is losing patent protections · Keytruda · beginning in 2028”
“Keytruda · accounts for · roughly half of Merck's revenue · true”
“Merck's management · contends · current pipeline could generate · more than $70 billion worth of annual revenue 10 years from now”
“IBM · has raised dividend · every year for the past 31 years · true”
“IBM · software accounts for · roughly 45% of its total revenue · true”
“The Motley Fool Stock Advisor analyst team · identified · the 10 best stocks for investors · true”
“Stock Advisor total average return · is · 968% · true”
“S&P 500 · is · 202% · true”
“Altara · announced · seed funding · $7 million”
“Greylock · led · seed funding · $7 million”
“Altara · empowers · physical sciences companies · transform their fragmented data into actionable intelligence”
“Altara · ensures · frontier innovation · is no longer constrained by legacy software and data systems”
